Opportunity Information: Apply for PA 10 129
Apply for PA 10 129
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Drug Abuse Aspects of HIV/AIDS (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Mar 11, 2010 and posted on Mar 11, 2010.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Independent school districts County governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Private institutions of higher education Small businesses For profit organizations other than small businesses Special district governments Native American tribal governments (Federally recognized) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Drug Abuse Aspects of HIV/AIDS (R01) opportunity (Funding Opportunity Number PA 10 129) is a National Institutes of Health (NIH) funding announcement led by the National Institute on Drug Abuse (NIDA). It invites full-scale Research Project Grant (R01) applications focused on the intersections between drug abuse, addiction, and HIV/AIDS. The central aim is to strengthen the evidence base on how drug use influences HIV risk, transmission, disease progression, and health outcomes, and to generate practical approaches that improve prevention and treatment for people who use drugs and for their sexual partners.
The scope is broad but clearly centered on drug-related drivers of the HIV epidemic. NIDA is looking for studies that examine drug-related risk behaviors (for example, behaviors linked to injection and non-injection drug use that increase exposure to HIV), the relationship between addiction and HIV disease (including how substance use and addiction may affect immune function, treatment adherence, and HIV progression), and the comorbidities and downstream consequences that occur when HIV and drug use intersect (such as co-occurring infections, mental health challenges, and other medical or social complications). A major emphasis is on research that can identify and predict shifts in HIV epidemiology among people who inject drugs, people who use drugs without injecting, and their sexual partners. In practice, that means proposals could address changing patterns of transmission, emerging risk networks, geographic or demographic shifts, and factors that signal where outbreaks or rising incidence might occur.
The announcement also strongly encourages intervention-focused work. This includes developing and testing primary prevention interventions (aimed at preventing HIV acquisition) and secondary prevention interventions (aimed at reducing transmission risk and improving outcomes among those already living with HIV). It supports research to improve HIV testing, counseling, and treatment services tailored to the needs and realities of people who use drugs, with the goal of improving diagnosis, linkage to care, retention in care, and treatment success. In addition to behavioral, clinical, and services research, the FOA explicitly includes basic and mechanistic studies that investigate HIV infection and AIDS pathogenesis in the context of drug abuse and addiction, recognizing that substances and addiction-related physiological changes may influence biological pathways relevant to infection, inflammation, or disease progression.
This funding opportunity uses the NIH R01 mechanism, which is generally intended for mature, hypothesis-driven projects that can support a substantial research plan over multiple years. The FOA notes that it runs in parallel with companion announcements of identical scientific scope that use different mechanisms: PA 10 130 for the R21 (often used for exploratory or developmental projects) and PA 10 131 for the R03 (often used for smaller, limited-scope studies). Applicants should choose the mechanism that best matches the maturity, scale, and risk level of the proposed work.
Funding levels and the number of awards are not fixed in the announcement because proposed projects can vary widely in size, complexity, duration, and cost. As a result, NIH anticipated that award size and length would differ across funded applications, and that the total number of awards and total dollars would depend on the scientific merit and budget needs of the applications received.
Eligibility is expansive and includes a wide range of organizations and governments. Eligible applicants include public and private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses and other for-profit organizations, independent school districts, and multiple levels of government (city/township, county, state, special district, and certain housing authorities). The announcement also includes tribal governments and tribal organizations, as well as specific categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations), among others. The listing indicates no cost sharing or matching requirement.
Key administrative details reflect that this was a discretionary grant opportunity in the health/education domain (CFDA 93.279, Drug Abuse and Addiction Research Programs). It was posted and created on March 11, 2010, with an original and final closing date of January 7, 2013, and an archive date of February 7, 2013, indicating the opportunity is no longer active. The full announcement was hosted on the NIH grants guide site (historically at the link provided in the notice), and NIH Office of Extramural Research (OER) webmaster contacts were listed for access or technical issues.
FAQs: Drug Abuse Aspects of HIV/AIDS (R01) (PA-10-129)
What is the Drug Abuse Aspects of HIV/AIDS (R01) funding opportunity?
It is a National Institutes of Health (NIH) funding announcement that invited full-scale Research Project Grant (R01) applications focused on the intersections between drug abuse, addiction, and HIV/AIDS, with the goal of improving prevention and treatment for people who use drugs and their sexual partners.
What is the Funding Opportunity Number (FON) for this announcement?
The Funding Opportunity Number is PA-10-129.
Which NIH institute leads this opportunity?
The opportunity is led by the National Institute on Drug Abuse (NIDA).
What grant mechanism does this announcement use?
This opportunity uses the NIH R01 mechanism (Research Project Grant), which is generally intended for mature, hypothesis-driven projects supporting a substantial research plan over multiple years.
What is the central aim of the research supported by this announcement?
The central aim is to strengthen the evidence base on how drug use influences HIV risk, transmission, disease progression, and health outcomes, and to generate practical approaches to improve prevention and treatment for people who use drugs and for their sexual partners.
What kinds of research topics are within scope?
The scope is broad but centered on drug-related drivers of the HIV epidemic. Topics include drug-related risk behaviors, the relationship between addiction and HIV disease, comorbidities and downstream consequences of intersecting HIV and drug use, intervention development and testing, services research to improve testing and treatment, and basic/mechanistic studies of HIV infection and AIDS pathogenesis in the context of drug abuse and addiction.
Does the announcement include research on both injection and non-injection drug use?
Yes. It includes research on people who inject drugs, people who use drugs without injecting, and their sexual partners, particularly where drug-related behaviors increase exposure to HIV.
What does the announcement mean by drug-related risk behaviors?
It refers to behaviors linked to injection and non-injection drug use that increase exposure to HIV and contribute to HIV risk and transmission.
Does the opportunity support research on how substance use affects HIV disease progression?
Yes. It includes the relationship between addiction and HIV disease, including how substance use and addiction may affect immune function, treatment adherence, and HIV progression.
Are comorbidities and downstream consequences part of the focus?
Yes. The scope includes comorbidities and downstream consequences when HIV and drug use intersect, such as co-occurring infections, mental health challenges, and other medical or social complications.
Is there an emphasis on predicting changes in HIV epidemiology among people who use drugs?
Yes. A major emphasis is on research that can identify and predict shifts in HIV epidemiology among people who inject drugs, people who use drugs without injecting, and their sexual partners.
What types of epidemiologic shifts are relevant?
Examples described include changing patterns of transmission, emerging risk networks, geographic or demographic shifts, and factors that signal where outbreaks or rising incidence might occur.
Does the announcement encourage intervention-focused research?
Yes. It strongly encourages intervention-focused work, including developing and testing primary and secondary prevention interventions.
What is meant by primary prevention interventions in this announcement?
Primary prevention interventions are aimed at preventing HIV acquisition.
What is meant by secondary prevention interventions in this announcement?
Secondary prevention interventions are aimed at reducing transmission risk and improving outcomes among people already living with HIV.
Does the opportunity support research to improve HIV testing, counseling, and treatment services?
Yes. It supports research to improve HIV testing, counseling, and treatment services tailored to the needs and realities of people who use drugs, with goals such as improving diagnosis, linkage to care, retention in care, and treatment success.
Are basic or mechanistic studies allowed under this announcement?
Yes. The announcement explicitly includes basic and mechanistic studies investigating HIV infection and AIDS pathogenesis in the context of drug abuse and addiction, recognizing that substances and addiction-related physiological changes may influence biological pathways relevant to infection, inflammation, or disease progression.
Are there related announcements with the same scientific scope but different mechanisms?
Yes. The FOA runs in parallel with companion announcements of identical scientific scope using different mechanisms: PA-10-130 (R21) and PA-10-131 (R03).
What are the companion FOAs and what mechanisms do they use?
The companion announcements are PA-10-130 for the R21 mechanism (often used for exploratory or developmental projects) and PA-10-131 for the R03 mechanism (often used for smaller, limited-scope studies).
How should an applicant choose between R01, R21, and R03 for this topic?
Applicants should choose the mechanism that best matches the maturity, scale, and risk level of the proposed work, with R01 generally used for mature, hypothesis-driven projects and R21/R03 aligned with exploratory or smaller-scope efforts.
Are funding levels or the number of awards fixed for this announcement?
No. Funding levels and the number of awards are not fixed because projects can vary widely in size, complexity, duration, and cost, and the total number of awards and dollars depends on scientific merit and budget needs of the applications received.
Is cost sharing or matching required?
No. The listing indicates there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is expansive and includes public and private institutions of higher education; nonprofits with and without 501(c)(3) status; small businesses and other for-profit organizations; independent school districts; and multiple levels of government including city/township, county, state, special district, and certain housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. The announcement includes tribal governments and tribal organizations, as well as Tribally Controlled Colleges and Universities (TCCUs).
Are specific institution types like HBCUs and Hispanic-serving institutions included as eligible applicants?
Yes. The eligibility listing includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and other specified categories.
Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are included among eligible applicants.
Are U.S. territories or possessions included in eligibility?
Yes. U.S. territories or possessions are included in the eligibility listing.
Can non-U.S. organizations apply?
Yes. The listing includes non-U.S. entities (foreign organizations) among eligible applicants.
What CFDA number is associated with this opportunity?
The CFDA is 93.279, Drug Abuse and Addiction Research Programs.
When was this opportunity posted and created?
It was posted and created on March 11, 2010.
What were the closing dates for this opportunity?
The original and final closing date was January 7, 2013.
Is this funding opportunity still active?
No. It has an archive date of February 7, 2013, which indicates the opportunity is no longer active.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants guide site (at the link provided in the notice).
Who was listed for access or technical issues related to the announcement?
NIH Office of Extramural Research (OER) webmaster contacts were listed for access or technical issues.
What type of grant opportunity was this described as administratively?
It was described as a discretionary grant opportunity in the health/education domain.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Drug Abuse Aspects of HIV/AIDS (R21)
Previous opportunity: Drug Abuse Aspects of HIV/AIDS (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 129
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 129) also looked into and applied for these:
| Funding Opportunity |
|---|
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 10 130 Funding Number: PA 10 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Medical Education Partnership Initiative (MEPI) (R24) Apply for RFA TW 10 008 Funding Number: RFA TW 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Research Education Program for Laboratory Animal Medicine Veterinarians (R25) Apply for RFA RR 10 002 Funding Number: RFA RR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $224,000 |
| Next Generation Genetic Association Studies (U01) Apply for RFA HL 11 006 Funding Number: RFA HL 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive Food Components (R21) Apply for PA 10 088 Funding Number: PA 10 088 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Development of Animal Models and Related Biological Materials For Research (R21) Apply for PA 10 138 Funding Number: PA 10 138 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Diet Composition and Energy Balance (R01) Apply for PA 10 152 Funding Number: PA 10 152 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Paul Calabresi Career Development Award for Clinical Oncology (K12) Apply for PAR 10 155 Funding Number: PAR 10 155 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identification and Characterization of Molecular Targets Within the mTOR Pathway With Potential to Impact Healthspan and Lifespan (R21) Apply for PA 10 164 Funding Number: PA 10 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cancer Institute (NCI) Cancer Education and Career Development Program (R25) Apply for PAR 10 165 Funding Number: PAR 10 165 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Academic Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) Apply for PAR 10 169 Funding Number: PAR 10 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25) Apply for PAR 10 173 Funding Number: PAR 10 173 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| International Research Ethics Education and Curriculum Development Award (R25) Apply for PAR 10 174 Funding Number: PAR 10 174 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 10 177 Funding Number: PAR 10 177 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Center of Excellence Grant Program (P50) Apply for PAR 10 189 Funding Number: PAR 10 189 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Independent Career Development Award for Biomedical Informatics (K22) Apply for PAR 10 195 Funding Number: PAR 10 195 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Centers of Biomedical Research Excellence (COBRE) Phase III Transitional Centers P30 Apply for PAR 10 196 Funding Number: PAR 10 196 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Information Resource Grants to Reduce Health Disparities (G08) Apply for RFA LM 10 001 Funding Number: RFA LM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| OVC FY 10 Mass Casualty and Violence at Home and Abroad Conference Apply for OVC 2010 2769 Funding Number: OVC 2010 2769 Agency: Office for Victims of Crime Category: Education Health Funding Amount: $655,000 |
| NCRR Science Education Partnership Award (SEPA) (R25) Apply for PAR 10 206 Funding Number: PAR 10 206 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 129", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.